Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.